Industry News
Pharmaceutical Industry News
Last year, Japan’s Renalys picked…
Last year, Japan's Renalys picked up certain Asian rights to the IgAN medicine sparsentan from the medicine's developer, Travere Therapeutics. Chugai is set to take the medicine forward in the licensed countries under a new
After a negative advisory…
After a negative advisory committee vote and a postponed approval decision, the FDA opted to approve GSK's Blenrep in one of its two proposed combinations.
The company expects sales in the…
The company expects sales in the second half of the year to outpace those from the first and reiterated its annual revenue guidance, projecting growth between 20% and 21% for all of 2025.
To reach the target audience of…
To reach the target audience of geographic atrophy (GA) treatment Izervay, Astellas Pharma has turned to the “internet’s grandma,” cookbook author and popular social media creator Barbara “Babs” Costello.
Among a string of licensing deals…
Among a string of licensing deals from the week, Takeda's tie-up with Innovent stole the show. Nkarta CEO Paul Hastings recently spoke to the importance of the industry's collaborations with Chinese biopharma companies. Asian biopharmas
Too old for pediatrics, too young…
Too old for pediatrics, too young for geriatrics - young adults with cancer are falling through the cracks. Here’s how we fix it.
In a new white paper, Havas Lynx…
In a new white paper, Havas Lynx lays out ways in which pharma marketers can—and should, according to the health comms agency—use their platforms to battle rampant misinformation.
Even as Roche executives on…
Even as Roche executives on Wednesday espoused confidence in the company’s resilience and growth potential over the next several years, a mix of exchange rate fluctuations and lackluster pharmaceutical sales led to a worse-than-expected third
Dermatology specialist Galderma…
Dermatology specialist Galderma has hopped on the U.S. manufacturing bandwagon, revealing a commitment to spend more than $650 million through 2030 as it taps domestic contractors to produce newly approved Nemluvio and other skincare treatments
Drug With a 30-Year Monopoly Is Target of State-Level Push to Curb Prices
In a first, Colorado will cap the price of Enbrel, an arthritis drug. Using patent tactics, the drugmaker Amgen has aggressively blocked competition for it.
Cambrex revealed plans to spend…
Cambrex revealed plans to spend $120 million to expand its Iowa manufacturing operations on the heels of a report last month that its owner was seeking a sale.
Cardiovascular Benefits of Wegovy Extend Beyond Weight Loss, Study Shows
An analysis found that a shrinking waist size was responsible for only around a third of the cardiovascular benefits in people who took Wegovy.
We’re at a tipping point in…
We’re at a tipping point in Alzheimer's disease, with new treatments, multiple validated targets and advanced CNS delivery methods converging.
Nephron Pharmaceuticals’…
Nephron Pharmaceuticals' manufacturing facility in West Columbia, South Carolina, is still running afoul of the FDA. In its most recent Form 483 report, the agency has cited several problems that were evident in an August
Johnson & Johnson is taking…
Johnson & Johnson is taking flight with the New York Jets, joining the NFL team’s roster in a multiyear agreement as its official medical innovation sponsor.
CDx innovation is reshaping…
CDx innovation is reshaping precision oncology—discover how decentralized testing is bringing diagnostics closer to patients.
Merck KGaA plans to discontinue…
Merck KGaA plans to discontinue operations at its production plant in Arklow, Ireland, “by the end of 2028,” a company spokesperson confirmed to Fierce Pharma. The decision follows a strategic review of the products made
Moderna is backing the American…
Moderna is backing the American Lung Association’s call for people with lung diseases to get vaccinated for the upcoming respiratory virus season.
Novartis has filed suit against…
Novartis has filed suit against AstraZeneca’s rare disease unit, claiming that certain marketing materials for Alexion’s Ultomiris create an inaccurate impression of Novartis’ rival drug Fabhalta.
With plans to pay $2.1 billion to…
With plans to pay $2.1 billion to acquire its Dublin, Ireland, neighbor Avadel Pharmaceuticals, Alkermes is hoping to gain an immediate growth driver in narcolepsy drug Lumryz. But perhaps more importantly, the deal lays the